Ncardia Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
55
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$51.9M
- Investors
-
11
Ncardia General Information
Description
Operator of a biotechnology research company intended to provide technologies to expedite drug discovery and development processes. The company uses human induced pluripotent stem cells technology to develop predictive human cellular assay systems for safety and efficacy testing of drug candidates, as well as enhance cardiovascular and neural drug screening, enabling researchers to bring predictive human disease biology and accelerate discovery.
Contact Information
Website
www.ncardia.comCorporate Office
- Biopartner building 1
- J.H. Oortweg 21
- 2333 BD Leiden
- Netherlands
Corporate Office
- Biopartner building 1
- J.H. Oortweg 21
- 2333 BD Leiden
- Netherlands
Ncardia Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 19-Sep-2024 | $51.9M | Completed | Generating Revenue | ||
| 5. Later Stage VC | 16-Nov-2021 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 15-Jul-2019 | Completed | Generating Revenue | |||
| 3. Grant | 05-Jul-2019 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series B) | 17-Nov-2017 | $12.4M | $16.6M | Completed | Generating Revenue | |
| 1. Merger of Equals | 18-Sep-2017 | $4.25M | $4.25M | Completed | Generating Revenue |
Ncardia Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class C | ||||||||
| Class B | ||||||||
| Class B | 262,052 | $44.9 | $44.9 | 1x | $44.9 | 18.94% |
Ncardia Comparisons
Industry
Financing
Details
Ncardia Competitors (121)
One of Ncardia’s 121 competitors is Maze Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Maze Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Valo Therapeutics | Venture Capital-Backed | Helsinki, Finland | ||||
| Verge Labs | Venture Capital-Backed | San Francisco, CA | ||||
| Precigen | Formerly VC-backed | Germantown, MD | ||||
| Orgenesis | Corporation | Germantown, MD |
Ncardia Patents
Ncardia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3186849-A1 | Closed manufacturing processes for large scale manufacturing of pluripotent stem cell derived cells | Pending | 23-Jul-2020 | ||
| WO-2022019768-A1 | Closed manufacturing processes for large scale manufacturing of pluripotent stem cell derived cells | Inactive | 23-Jul-2020 | ||
| EP-3684917-A1 | In vitro method for providing stem cell derived cardiomyocytes | Inactive | 22-Sep-2017 | ||
| US-20210147805-A1 | In vitro method for providing stem cell derived cardiomyocytes | Inactive | 22-Sep-2017 | ||
| WO-2019059769-A1 | In vitro method for providing stem cell derived cardiomyocytes | Inactive | 22-Sep-2017 | C12N5/0657 |
Ncardia Signals
Ncardia Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Kiniciti | PE-Backed Company | Minority | ||
| Mibiton | Venture Capital | Minority | ||
| Noshaq | Venture Capital | Minority | ||
| Sino-German High Tech Fund | Venture Capital | Minority | ||
| Health ~ Holland | Government |
Ncardia Acquisitions (3)
Ncardia’s most recent deal was a Merger/Acquisition with Celyad Oncology (Manufacturing Business Unit) for . The deal was made on 20-Sep-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Celyad Oncology (Manufacturing Business Unit) | 20-Sep-2022 | Merger/Acquisition | Biotechnology | ||
| Axiogenesis | 18-Sep-2017 | Merger/Acquisition | Biotechnology | ||
| Pluriomics | 18-Sep-2017 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Ncardia FAQs
-
When was Ncardia founded?
Ncardia was founded in 2010.
-
Where is Ncardia headquartered?
Ncardia is headquartered in Leiden, Netherlands.
-
What is the size of Ncardia?
Ncardia has 55 total employees.
-
What industry is Ncardia in?
Ncardia’s primary industry is Drug Discovery.
-
Is Ncardia a private or public company?
Ncardia is a Private company.
-
What is the current valuation of Ncardia?
The current valuation of Ncardia is .
-
What is Ncardia’s current revenue?
The current revenue for Ncardia is .
-
How much funding has Ncardia raised over time?
Ncardia has raised $130M.
-
Who are Ncardia’s investors?
Kiniciti, Mibiton, Noshaq, Sino-German High Tech Fund, and Health ~ Holland are 5 of 11 investors who have invested in Ncardia.
-
Who are Ncardia’s competitors?
Maze Therapeutics, Valo Therapeutics, Verge Labs, Precigen, and Orgenesis are some of the 121 competitors of Ncardia.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process